ClinicalTrials.gg
CompletedNCT01089751Updated Sep 26, 2013Results posted

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

A Phase 4 interventional study of trospium chloride and placebo in Overactive Bladder, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-09-26.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Urinary Bladder, Overactive by AbbVie — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · AbbVie.

Enrollment
9th of 22
322 · median 265
Started
2010
with 3 others
Phase 4
9 of 28
none open now
Registered
15th of 28
by date

Among the 28 studies in Urinary Bladder, Overactive by AbbVie, this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2010, is one of 9 in phase 4, and was the 15th registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 127 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

None of the 28 studies in Urinary Bladder, Overactive by AbbVie is open now. The open studies under Urinary Bladder, Overactive, anywhere →

Who these studies take

Of the 74 Urinary Bladder, Overactive studies recruiting now, 44 (59%) set no upper age limit and 16 (22%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Urinary Bladder, Overactive by AbbVie as a file.
02

Study summary

This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.

03

Conditions studied

  • Overactive Bladder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Taking Detrol® LA 4mg daily for a minimum of 1 month prior to Screening/Qualification
  • Overactive Bladder syndrome with urgency, urinary frequency and urgency urinary incontinence
  • Taking five or more concomitant medications (may be prescription, non-prescription, or supplement/vitamin) daily for indications other than Overactive Bladder (OAB).

Exclusion criteria

Exclusion Criteria:

  • Predominant stress or insensate incontinence
  • History of neurogenic bladder
  • Two urinary tract infections in the last six months
  • Gastric by-pass (Roux-en-Y) surgery (adjustable gastric banding is allowed)
  • Donated >500mL blood in the 30 days prior to the screening visit
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    Sanctura XR®

    Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.

    Drug: trospium chloride

  • Placebo comparator
    Placebo

    Placebo once daily on an empty stomach for 14 weeks.

    Drug: placebo

Interventions

  • Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks

    Also known as: Sanctura XR®

  • Drugplacebo

    Placebo once daily on an empty stomach for 14 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Continent (PPC)

    PPC is the percentage of patients with complete continence (without any urgency urinary incontinence episodes) during the 3-day bladder diary period associated with the Week 14 visit.

    Time frame: Week 14

Secondary outcomes

  1. Change From Baseline in Continent Days Per Week (CDW)

    Continent Days per Week is the average of the number of times an individual has no incontinence episodes in a day within the 3-day collection period calculated as 7 x (number of dry days within the 3-day diary period) divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A positive change from Baseline (more continent/fewer incontinent days per week ) indicated improvement.

    Time frame: Baseline, Week 14

  2. Change From Baseline in Nocturic Toilet Voids

    A nocturic (nighttime) toilet void is identified if the patient marks "Yes" for both Toilet Voiding and Sleep Interruption in the 3-day bladder diary. The daily average number of nocturic toilet voids is obtained as the sum of all nighttime toilet voids over the 3-day bladder diary period divided by number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer nocturic toilet voids) indicated improvement.

    Time frame: Baseline, Week 14

  3. Change From Baseline in Urgency-Related Toilet Voids

    Urgency-related toilet void (or urinary urgency) is identified if the patient marks "Yes" for both Urgency Association Void and Toilet Voiding in the 3-day bladder diary. The daily average number of urgency-related voids is calculated as the sum of all urgency episodes over the 3-day bladder diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer urgency related toilet voids) indicated improvement.

    Time frame: Baseline, Week 14

  4. Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)

    The OAB-SCS is derived from the 3-day bladder diary which includes: 1) 24-hour voiding frequency; 2) the Indevus Urgency Severity Scale (IUSS) Score (0=no urgency, 1=aware of urgency but is tolerable, 2=urgency discomfort interferes with activities/tasks, 3=extreme urgency discomfort that abruptly stops activities/tasks associated with each toilet void); and 3) the frequency of Urgency Urinary Incontinence episodes. Each toilet void is then assigned a point value from 1 (IUSS Score=0) to 5 (UUI episode not associated with a toilet void). The daily average OAB-SCS is then calculated based on the diary entries and assigned point values. The lowest possible daily average OAB-SCS is 0 (corresponding to no urgency in every void). There is no upper limit since the score is based on the number of voids per day. Scores \<= 30 indicate mild OAB, scores \> 30 to 39 indicate moderate OAB, and scores \>= 40 indicate severe OAB. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 14

  5. Change From Baseline in Voided Volume

    Average volume of urine voided per toilet void is calculated by total volume collected in a 24-hour diary period divided by the number of individual entries of volume voided in that period. A positive change from Baseline (greater volume voided) indicated improvement. A negative change from Baseline (less volume voided) indicated a worsening.

    Time frame: Baseline, Week 14

  6. Change From Baseline in Urgency Severity

    The urgency severity per toilet void is based on the Indevus Urgency Severity Scale (IUSS). The patient recorded urinary urgency severity in a 3-day bladder diary using a 4-point scale: 0=None-no urgency (best), 1=Slight-aware of urgency but is tolerable, 2=Moderate-urgency discomfort interferes with activities/tasks, 3=Severe-extreme urgency discomfort that abruptly stops activities/tasks (worst). Urgency Severity is calculated as the sum of all IUSS scores during the 3-day diary period divided by the number of toilet voids recorded during that period. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 14

  7. Change From Baseline in Urgency Urinary Incontinence (UUI)

    Urgency urinary incontinence is identified if the patient marks "Yes" for both Accidental Leakage and Urgency Associated Void in the 3-day bladder diary, and the Urgency Severity score is ≥ 1. Average daily episodes of UUI is calculated as the sum of all UUI episodes over 3-day diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Week 14

07

Results

Posted Sep 26, 2013

Participant flow

Participant flow — Overall Study
MilestoneSanctura XR®Placebo
Started163159
Completed129132
Not completed3427

Outcome measures

PrimaryPercentage of Patients Continent (PPC)

PPC is the percentage of patients with complete continence (without any urgency urinary incontinence episodes) during the 3-day bladder diary period associated with the Week 14 visit.

Time frame:
Week 14
Reported as:
Number · Percentage of participants
Percentage of Patients Continent (PPC)
Percentage of participantsSanctura XR®Placebo
Percentage of Patients Continent (PPC)34.617.1
SecondaryChange From Baseline in Continent Days Per Week (CDW)

Continent Days per Week is the average of the number of times an individual has no incontinence episodes in a day within the 3-day collection period calculated as 7 x (number of dry days within the 3-day diary period) divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A positive change from Baseline (more continent/fewer incontinent days per week ) indicated improvement.

Time frame:
Baseline, Week 14
Reported as:
Mean · Continent days per week
Change From Baseline in Continent Days Per Week (CDW)
Continent days per weekSanctura XR®Placebo
Baseline0.8 ± 1.461.0 ± 1.52
Change from Baseline at Week 142.6 ± 2.961.3 ± 2.73
SecondaryChange From Baseline in Nocturic Toilet Voids

A nocturic (nighttime) toilet void is identified if the patient marks "Yes" for both Toilet Voiding and Sleep Interruption in the 3-day bladder diary. The daily average number of nocturic toilet voids is obtained as the sum of all nighttime toilet voids over the 3-day bladder diary period divided by number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer nocturic toilet voids) indicated improvement.

Time frame:
Baseline, Week 14
Reported as:
Mean · Nocturic toilet void
Change From Baseline in Nocturic Toilet Voids
Nocturic toilet voidSanctura XR®Placebo
Baseline2.2 ± 1.402.3 ± 1.41
Change from Baseline at Week 14-0.6 ± 1.51-0.3 ± 1.42
SecondaryChange From Baseline in Urgency-Related Toilet Voids

Urgency-related toilet void (or urinary urgency) is identified if the patient marks "Yes" for both Urgency Association Void and Toilet Voiding in the 3-day bladder diary. The daily average number of urgency-related voids is calculated as the sum of all urgency episodes over the 3-day bladder diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer urgency related toilet voids) indicated improvement.

Time frame:
Baseline, Week 14
Reported as:
Mean · Toilet void
Change From Baseline in Urgency-Related Toilet Voids
Toilet voidSanctura XR®Placebo
Baseline7.6 ± 3.367.5 ± 3.62
Change from Baseline at Week 14-2.3 ± 3.78-1.6 ± 3.87
SecondaryChange From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)

The OAB-SCS is derived from the 3-day bladder diary which includes: 1) 24-hour voiding frequency; 2) the Indevus Urgency Severity Scale (IUSS) Score (0=no urgency, 1=aware of urgency but is tolerable, 2=urgency discomfort interferes with activities/tasks, 3=extreme urgency discomfort that abruptly stops activities/tasks associated with each toilet void); and 3) the frequency of Urgency Urinary Incontinence episodes. Each toilet void is then assigned a point value from 1 (IUSS Score=0) to 5 (UUI episode not associated with a toilet void). The daily average OAB-SCS is then calculated based on the diary entries and assigned point values. The lowest possible daily average OAB-SCS is 0 (corresponding to no urgency in every void). There is no upper limit since the score is based on the number of voids per day. Scores \<= 30 indicate mild OAB, scores \> 30 to 39 indicate moderate OAB, and scores \>= 40 indicate severe OAB. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 14
Reported as:
Mean · Score on a scale
Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)
Score on a scaleSanctura XR®Placebo
Baseline24.6 ± 9.0723.7 ± 10.70
Change from Baseline at Week 14-6.5 ± 10.23-3.4 ± 11.44
SecondaryChange From Baseline in Voided Volume

Average volume of urine voided per toilet void is calculated by total volume collected in a 24-hour diary period divided by the number of individual entries of volume voided in that period. A positive change from Baseline (greater volume voided) indicated improvement. A negative change from Baseline (less volume voided) indicated a worsening.

Time frame:
Baseline, Week 14
Reported as:
Mean · cubic centimeters (cc)
Change From Baseline in Voided Volume
cubic centimeters (cc)Sanctura XR®Placebo
Baseline183.5 ± 79.78187.4 ± 78.76
Change from Baseline at Week 1420.6 ± 89.62-8.0 ± 71.56
SecondaryChange From Baseline in Urgency Severity

The urgency severity per toilet void is based on the Indevus Urgency Severity Scale (IUSS). The patient recorded urinary urgency severity in a 3-day bladder diary using a 4-point scale: 0=None-no urgency (best), 1=Slight-aware of urgency but is tolerable, 2=Moderate-urgency discomfort interferes with activities/tasks, 3=Severe-extreme urgency discomfort that abruptly stops activities/tasks (worst). Urgency Severity is calculated as the sum of all IUSS scores during the 3-day diary period divided by the number of toilet voids recorded during that period. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 14
Reported as:
Mean · Score on a scale
Change From Baseline in Urgency Severity
Score on a scaleSanctura XR®Placebo
Baseline1.4 ± 0.601.3 ± 0.56
Change from Baseline at Week 14-0.4 ± 0.67-0.3 ± 0.60
SecondaryChange From Baseline in Urgency Urinary Incontinence (UUI)

Urgency urinary incontinence is identified if the patient marks "Yes" for both Accidental Leakage and Urgency Associated Void in the 3-day bladder diary, and the Urgency Severity score is ≥ 1. Average daily episodes of UUI is calculated as the sum of all UUI episodes over 3-day diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Week 14
Reported as:
Mean · UUI episodes
Change From Baseline in Urgency Urinary Incontinence (UUI)
UUI episodesSanctura XR®Placebo
Baseline2.9 ± 2.993.0 ± 2.72
Change from Baseline at Week 14-1.1 ± 2.24-0.6 ± 2.22

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sanctura XR®—2/162 (1.2%)20/162 (12.3%)
Placebo—3/158 (1.9%)8/158 (5.1%)
Most frequent serious events
Most frequent serious events
EventSanctura XR®Placebo
Pericardial effusionCardiac disorders0/1621/158
Pyelonephritis acuteInfections and infestations0/1621/158
Diabetes mellitusMetabolism and nutrition disorders0/1621/158
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1621/158
AnaemiaBlood and lymphatic system disorders1/1620/158
Gastrooesophageal reflux diseaseGastrointestinal disorders1/1620/158
GastroenteritisInfections and infestations1/1620/158
Most frequent other events
Most frequent other events
EventSanctura XR®Placebo
Dry mouthGastrointestinal disorders11/1626/158
ConstipationGastrointestinal disorders9/1622/158

Baseline characteristics

Age Continuous
Age Continuous(Years)Sanctura XR®PlaceboTotal
Mean56.3 (21 to 76)56.0 (21 to 84)56.1 (21 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Sanctura XR®PlaceboTotal
Female163159322
Male000
08

Study locations

1 site
  • La Mesa, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2010
First posted
Mar 19, 2010
Start
Mar 2010
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Sep 26, 2013
Last update
Sep 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01089751
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Mar 19, 2010
Start date
Mar 2010
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Sep 26, 2013
Last update
Sep 26, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trospium chloride

Start the discussion